OCULAR THERAPEUTIX, INC (OCUL) Stock
5 of the hedge funds AlphaScala tracks reported OCUL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $32.33M. Company insiders reported 0 open-market buys and 8 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own OCUL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 3.29M | $32.33M | -41% |
| Renaissance Technologies Jim Simons (founder) | 379K | $3.72M | -67% |
| Citadel Ken Griffin | 310K | $3.05M | -51% |
| Marshall Wace | 126K | $1.24M | -83% |
| D.E. Shaw David Shaw | 124K | $1.22M | -43% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are OCULAR THERAPEUTIX, INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 8, 26 | Anderman Todd | Chief Legal Officer | SELL | 12.0K | $87K |
| Oct 2, 26 | Heier Jeffrey S. | Chief Scientific Officer | SELL | 10.9K | $77K |
| Oct 2, 26 | Kaiser Peter | Chief Development Officer | SELL | 10.0K | $70K |
| Aug 31, 26 | Notman Donald | Chief Operating Officer | SELL | 1.1K | $11K |
| Aug 24, 26 | Dugel Pravin | See Remarks | SELL | 21.6K | $233K |
| Aug 24, 26 | Heier Jeffrey S. | Chief Scientific Officer | SELL | 3.3K | $36K |
| Aug 24, 26 | Nayak Sanjay | Chief Strategy Officer | SELL | 1.9K | $20K |
| Aug 24, 26 | Kaiser Peter | Chief Development Officer | SELL | 3.0K | $33K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →OCUL price chart
Powered by TradingViewWhat does OCULAR THERAPEUTIX, INC do?
Ocular Therapeutix Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. It specializes in ophthalmology, particularly advancing treatments for retinal disorders such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR). The company's pipeline features AXPAXLI (OTX-TKI), a tyrosine kinase inhibitor delivered via intravitreal bioresorbable implant designed for extended durability, currently in late-stage Phase 3 clinical programs including the SOL-1 superiority trial and HELIOS registrational program. Ocular Therapeutix Inc. also markets DEXTENZA, a commercial intracanalicular insert for ocular pain and inflammation post-surgery. Additional candidates like OTX-TP target glaucoma and dry eye disease. Headquartered in Bedford, Massachusetts and founded in 2006, the company plays a key role in the retinal therapeutics market by leveraging bioresorbable hydrogel technology to improve patient outcomes and reduce treatment burden through sustained drug delivery systems.